Unusually High Rates of Hepatocellular Carcinoma After Treatment With Direct-Acting Antiviral Therapy for Hepatitis C Related Cirrhosis

Gastroenterology

Volumn 152, Issue 4, 2017, Pages 911-912

  Ravi, Sujan ^a   Axley, Page ^a   Jones, DeAnn ^b   Kodali, Sudha ^b   Simpson, Heather ^b   McGuire, Brendan M ^b   Singal, Ashwani K ^b  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; LEDIPASVIR; SOFOSBUVIR; ANTIVIRUS AGENT;

ADULT; ANTIVIRAL THERAPY; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HEPATITIS C; HUMAN; LETTER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; PRIORITY JOURNAL; RECURRENCE RISK; SUSTAINED VIROLOGIC RESPONSE; AGED; COMPLICATION; LIVER TUMOR; MIDDLE AGED; RETROSPECTIVE STUDY; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

AGED; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 85014333132     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2016.12.021     Document Type: Letter

References (8)

1. 1 Lawitz, E., et al. Gastroenterology 149 (2015), 971–980.e1.
2. 2 Kuo, A., et al. Gastroenterology 149 (2015), 649–659.
3. 3 Bruix, J., et al. Hepatology 53 (2011), 1020–1022.
4. 4 Reig, M., et al. J Hepatol 65 (2016), 719–726.
5. 5 Conti, F., et al. J Hepatol 65 (2016), 727–733.
6. 6 ANRS Collaborative Study Group on Hepatocellular Carcinoma. J Hepatol 65 (2016), 734–740.
7. 7 Foster, G.R., et al. J Hepatol 64 (2016), 1224–1231.
8. 8 Farazi, P.A., et al. Nat Rev Cancer 6 (2006), 674–687.